ICR, Wellcome Trust, Illumina Launch Clinical Genetic Testing Effort | GenomeWeb

NEW YORK (GenomeWeb News) – A consortium of research centers led by the Institute of Cancer Research, London will partner with Illumina to launch a new sequencing-based testing program to analyze genetic mutations in cancer patients, the Wellcome Trust said today.

Funded with £2.7 million ($4.1 million) from the Wellcome Trust, the Mainstreaming Cancer Genetics program will incorporate Illumina's TruSight Cancer panel into clinical care as part of a three-year pilot project.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.